146 related articles for article (PubMed ID: 21658630)
1. Medical needs of cystic fibrosis patients and policies for fair co-operation between small and middle-sized companies and patient organizations.
Schlangen M; Reimann AL
J Cyst Fibros; 2011 Jun; 10 Suppl 2():S110-3. PubMed ID: 21658630
[TBL] [Abstract][Full Text] [Related]
2. Developing new products in cystic fibrosis: needs and obstacles for activities of small and middle-sized companies.
Schlangen M; Reimann AL
J Cyst Fibros; 2011 Jun; 10 Suppl 2():S103-9. PubMed ID: 21658629
[TBL] [Abstract][Full Text] [Related]
3. [Introductory overview article: internationalization of the health care industry].
von Bandemer S; Blank W; Büchel D
Z Evid Fortbild Qual Gesundhwes; 2011; 105(8):607-15. PubMed ID: 22142884
[No Abstract] [Full Text] [Related]
4. The shape of European business in 2003.
Wagner M
Med Device Technol; 2002 Dec; 13(10):8-10. PubMed ID: 12575520
[No Abstract] [Full Text] [Related]
5. Medicine's NFL draft.
Griffin F
J Ark Med Soc; 2009 Oct; 106(4):78. PubMed ID: 19813393
[No Abstract] [Full Text] [Related]
6. [An analysis of the pharmaceuticals market in Vietnam].
Simonet D
Sante; 2001; 11(3):155-60. PubMed ID: 11641078
[TBL] [Abstract][Full Text] [Related]
7. Mirror, mirror on the wall--evaluating Fair Market Value for manufacturer-physician consulting arrangements.
Eaton F; Reid J
Food Drug Law J; 2010; 65(1):141-57, iii. PubMed ID: 24475537
[TBL] [Abstract][Full Text] [Related]
8. Healthcare expenditures for privately insured people with cystic fibrosis.
Ouyang L; Grosse SD; Amendah DD; Schechter MS
Pediatr Pulmonol; 2009 Oct; 44(10):989-96. PubMed ID: 19768806
[TBL] [Abstract][Full Text] [Related]
9. Private company profiles.
Nat Biotechnol; 2003 Jul; 21 Suppl():BE23-8. PubMed ID: 12874973
[No Abstract] [Full Text] [Related]
10. India's growing clinical research sector: opportunity for global companies.
Varawalla N
IDrugs; 2007 Jun; 10(6):391-4. PubMed ID: 17642002
[TBL] [Abstract][Full Text] [Related]
11. Deal watch: M&A activity in 2009.
Walker J
Nat Rev Drug Discov; 2010 Feb; 9(2):95. PubMed ID: 20118956
[No Abstract] [Full Text] [Related]
12. Public-private partnerships boost research on neglected diseases.
Louët S
Nat Biotechnol; 2003 Nov; 21(11):1254-5. PubMed ID: 14595339
[No Abstract] [Full Text] [Related]
13. Oversight of marketing relationships between physicians and the drug and device industry: a comparative study.
Jost TS
Am J Law Med; 2010; 36(2-3):326-42. PubMed ID: 20726399
[TBL] [Abstract][Full Text] [Related]
14. Procurement and competition. Regulation is a bone of contention.
Moore A
Health Serv J; 2014 Jan; 124(6382):26-7. PubMed ID: 24640450
[No Abstract] [Full Text] [Related]
15. [Does the public sector have an independent research role in the development of drugs?].
Poulsen HE; Grønlykke TB
Ugeskr Laeger; 2003 Apr; 165(16):1674-6. PubMed ID: 12756828
[TBL] [Abstract][Full Text] [Related]
16. The Small- and Medium-sized Enterprises Office (SME Office) at the European Medicines Agency.
Carr M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):20-3. PubMed ID: 20101799
[TBL] [Abstract][Full Text] [Related]
17. Switzerland: a receptive market.
Med Device Technol; 2000 Nov; 11(9):56-7. PubMed ID: 11149350
[No Abstract] [Full Text] [Related]
18. The innovative medicines initiative: a European response to the innovation challenge.
Goldman M
Clin Pharmacol Ther; 2012 Mar; 91(3):418-25. PubMed ID: 22318619
[TBL] [Abstract][Full Text] [Related]
19. [Commercialization of results of intellectual activities in pharmaceutical industry].
Posylkina OV; Timaniuk VN; Gladukh EV
Lik Sprava; 2002; (8):16-9. PubMed ID: 12669531
[TBL] [Abstract][Full Text] [Related]
20. Being sucessfully disruptive.
Hogan J
Med Device Technol; 2005 Jun; 16(5):21, 23. PubMed ID: 15984542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
